GILD Gilead Sciences Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: GILD
  4. Earnings
?
Relative Growth: Rel. Growth: 50
Relative Strength: Rel. Strength: 56
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 30

EPS in 2026 (TTM): -$2.6

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the EPS for the trailing twelve months is -$2.6. Gilead Sciences's EPS for 2025 amounted to $6.84, marking an increase from $0.38 in 2024. During the quarterly period ending on Jun 30, 2026, GILD's EPS stood at -$8.45.

GILD earnings history

Historical annual and quarterly earnings per share (EPS) data for Gilead Sciences
EPS (TTM)
-$2.6
EPS Growth YoY (Quarterly)
-638.2%
EPS (Quarterly)
-$8.45
EPS Growth (Quarterly)
-618.4%

Gilead Sciences had an annual EPS of $6.84, indicating an increase of 1,700% from $0.38 in 2024. The quarterly per-share earnings for the period ending Jun 30, 2026, was -$8.45, indicating a 638.2% decrease from the same quarter last year. GILD's 12-month EPS stands at -$2.6 as of June 2026. Gilead Sciences's annual EPS in 2024 stood at $0.38, a 91.6% decrease year-over-year.

GILD EPS vs price chart

GILD EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-638.2%
EPS growth YoY
1,700%
EPS growth 3Y avg
23.2%
EPS growth 5Y avg
132.8%

During the last 12 months, Gilead Sciences has seen an EPS growth of -638.2% (YoY, quarterly). Throughout the last three years, the company had an average EPS growth of 23.2% per year. During the last 5 years, the company had an average EPS growth rate of 132.8%. When measured over a ten-year period, GILD's average EPS growth rate was -5.8%.

GILD Earnings Waterfall

Breakdown of revenue, profit and net income for Gilead Sciences

GILD Earnings vs Peers

What are the earnings of GILD compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
QGEN Qiagen NV 22.83 415.8% 1.8% 3.9%
AMGN AMGEN Inc 27.09 88.1% 5.6% 2.9%
JNJ Johnson & Johnson 30.96 90.6% 17.7% 14.8%
VRTX Vertex Pharmaceuticals Inc 31.62 843.3% 6% 8.2%
PFE Pfizer Inc 36.93 -3.5% -37.4% -3.7%
BIIB Biogen Inc 38.17 -21.2% -25% -18.7%
ILMN Illumina Inc 40.63 171.1% N/A 4.1%
LLY Lilly(Eli) & Company 42.07 95.6% 49.2% 27.5%
ABBV Abbvie Inc 74.64 -1.3% -29.1% -2.8%
MRK Merck & Co Inc 120.12 8% 8.4% 21.2%
GILD Gilead Sciences Inc N/A 1,700% 23.2% 132.8%

All data is based on quarterly TTM periods, unless otherwise specified.